Loading...
Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lipoprotein (LDL) receptor and an important regulator of LDL metabolism. Elevated PCSK9 levels have been associated with cardiovascular risk. The purpose of this study was to investigate how...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Public Library of Science
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3609731/ https://ncbi.nlm.nih.gov/pubmed/23544125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0060095 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|